112 completed, 24 terminated, 4 active not recruiting, 4 recruiting. 148 Phase 1, 41 Phase 2.
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg - Myeloproliferative Neoplasm | Phase 1 | Terminated | Joseph Jurcic | 2 | 2022-01-28 | 2024-04-23 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Bosutinib - Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia | Phase 1 / Phase 2 | Active not recruiting | Children's Oncology Group | 60 | 2020-07-06 | 2026-10-01 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Ponatinib - Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Incyte Biosciences International Sàrl | 70 | 2020-01-29 | 2026-10-09 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 242 | 2020-01-09 | 2025-11-05 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy Edetate Calcium Disodium, Multivitamin, Succimer - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 58 | 2018-10-11 | 2026-09-18 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia Axitinib, Bosutinib, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML) | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-03-20 | 2020-11-19 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2017-01-18 | 2023-02-16 |
| PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies XmAb14045 - Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Xencor, Inc. | 120 | 2016-08-01 | 2022-03-08 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil - Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome | Phase 1 | Terminated | Stanford University | 1 | 2016-02-01 | 2018-09-12 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Adavosertib, Belinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2015-08-18 | 2026-01-30 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Bosutinib, Inotuzumab Ozogamicin - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2015-04-16 | 2023-07-17 |
| An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) MEK-162, Nilotinib, Questionnaires - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2015-03-11 | 2020-02-12 |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML metformin hydrochloride, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Northwestern University | 2 | 2015-03-11 | 2019-01-31 |
Showing 20 of 148. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (118) · Leukemia, Myeloid, Acute (113) · Leukemia (82) · Leukemia, Myeloid, Accelerated Phase (80) · Leukemia, Myeloid, Chronic-Phase (62) · Myelodysplastic Syndromes (61) · Leukemia, Lymphocytic, Chronic, B-Cell (56) · Leukemia, Myelomonocytic, Chronic (53) · Congenital Abnormalities (50) · Lymphoma, Non-Hodgkin (48) · Burkitt Lymphoma (47) · Lymphoma, Large B-Cell, Diffuse (47) · Lymphoma, Mantle-Cell (46) · Lymphoma, Follicular (45)
Bone Marrow Diseases (148) · Carcinogenesis (148) · Cell Transformation, Neoplastic (148) · Chronic Disease (148) · Disease Attributes (148) · Hemic and Lymphatic Diseases (148) · Neoplasms by Histologic Type (148) · Neoplastic Processes (148) · Pathologic Processes (148) · Pathological Conditions, Signs and Symptoms (148) · Hematologic Diseases (147) · Leukemia, Myeloid (145) · Neoplasms (142) · Immune System Diseases (122) · Immunoproliferative Disorders (122)
Peripheral Blood Stem Cell Transplantation (19) · Cyclophosphamide (15) · Cytarabine (14) · Filgrastim (14) · Tacrolimus (13) · Imatinib Mesylate (12) · fludarabine phosphate (12) · Busulfan (10) · Etoposide (10) · Mycophenolic Acid (8) · Cyclosporine (7) · Dasatinib (7) · Methotrexate (7) · Vorinostat (7) · Carboplatin (6)
National Cancer Institute (NCI) (33) · M.D. Anderson Cancer Center (18) · Fred Hutchinson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Case Comprehensive Cancer Center (3) · Masonic Cancer Center, University of Minnesota (3) · Northwestern University (3) · Vion Pharmaceuticals (3) · Virginia Commonwealth University (3) · Asan Medical Center (2) · Barbara Ann Karmanos Cancer Institute (2) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Indiana University (2)
United States (136) · Canada (10) · Italy (3) · France (2) · Germany (2) · Netherlands (2) · South Korea (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Belgium (1) · New Zealand (1) · Sweden (1)
Judith E. Karp, MD (4) · Jorge Cortes (3) · Jorge Cortes, MD (3) · Steven Grant, MD (3) · Ann E. Woolfrey, MD (2) · Brenda W. Cooper, MD (2) · Farhad Ravandi-Kashani (2) · Francis Giles (2) · Joseph G. Jurcic, MD (2) · Kenneth G. Lucas, MD (2) · Kyoo H. Lee, MD (2) · Mario Sznol, MD (2) · Maryam Fouladi (2) · Olatoyosi Odenike (2) · Richard Aplenc (2)
PMID 12114413, PMID 15570084, PMID 16278404, PMID 16775234, PMID 17562873, PMID 17640728, PMID 17971589, PMID 18327587, PMID 18571721, PMID 19139736, PMID 19179301, PMID 20460644, PMID 20511167, PMID 20858843, PMID 20860038, PMID 20952518, PMID 21403127, PMID 21791475, PMID 22009536, PMID 22430088, PMID 23393050, PMID 23443507, PMID 24530972, PMID 26210442, PMID 34312462, PMID 35982483, PMID 37647601, PMID 38033284, PMID 38683966, PMID 39570620, PMID 39863139, PMID 42784255
U01CA062461 (7), P30CA016672 (5), U01CA097452 (5), P30CA006973 (4), P30CA015704 (3), P30CA043703 (3), U01CA062502 (3), U01CA062505 (3), 2023 (2), P01CA018029 (2), P30CA016056 (2), P30CA016059 (2), P30CA072720 (2), U01CA062487 (2), U01CA062491 (2)